Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Tumor Necrosis Factor (TNF) Inhibitors Market 2018-2026: A $181.13 Billion Market Opportunity by 2026

Research and Markets
Posted on: 02 Jul 18
Global Tumor Necrosis Factor (TNF) Inhibitors Market 2018-2026: A $181.13 Billion Market Opportunity by 2026

PR Newswire

DUBLIN, July 2, 2018

DUBLIN, July 2, 2018 /PRNewswire/ --

The "Global Tumor Necrosis Factor (TNF) Inhibitors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.


The tumor necrosis factor inhibitors market was valued at US$ 43.39 Bn in 2017 and expected to reach US$ 181.13 Bn by 2026, expanding at a CAGR of 16.5% from 2018 to 2026.

Only five approved TNF inhibitors dominate the current market namely, adalimumab, certolizumab, etanercept, golimumab and infliximab. The extensive application of these approved drugs for various autoimmune conditions ensures continuous market growth during the forecast period from 2018 to 2026.

Approval of biosimilars would further add to the lucrativeness of this market. Biosimilars will intensify the market competition in TNF inhibitors market as several industrial players are currently investing in their development.

High prevalence of chronic conditions such as Crohn's disease, ulcerative colitis, plaque psoriasis, rheumatoid arthritis & others, continuous research activities in developing target-based biologics, provision of structured reimbursement policies and growing inclination towards cost-efficient biosimilars in developing economies contribute to the remunerative growth of this market.

Additionally, rising prevalence of chronic autoimmune disease such as Crohn's disease, rheumatoid arthritis, plaque psoriasis and ulcerative colitis increase the need for target based therapies such as TNF inhibitors.

TNF inhibitors market has been segmented based on drug type which comprises approved TNF inhibitors as mentioned above and various applications of TNF inhibitors namely, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ulcerative colitis, ankylosing spondylitis, hidradenitis suppurativa, uveitis and juvenile arthritis.

Crohn's disease segment projected with fastest CAGR owing to its growing prevalence across geographies and rising awareness on the efficiency of TNF inhibitors. As per the Centers for Disease Control and Prevention (CDC), around 201 cases of Crohn's disease per 100,000 adults observed in 2015. The prevalence will grow further during the forecast period owing to growing adoption of unhealthy dietary habits.

Based on geographical demarcation, North America dominated the market in 2017 with a market share of over 40% and expected to maintain this position throughout the forecast period. Patent exclusivity of approved TNF inhibitors for longer duration ensures maximum lucrativeness in this market.

Asia Pacific exhibited fastest growth during the forecast period. Increase in prevalence of autoimmune diseases, rising awareness on efficacy and availability of TNF inhibitors, growing investments of various industrial players in biosimilars and increased support from regulatory boards for biosimilar approval is expected to catalyze the overall market growth in Asia Pacific.

Key Market Movements


  • Globally tumor necrosis factor inhibitors market witnesses a remunerative growth with a CAGR of 16.5 % during the forecast period from 2018 to 2026
  • Constant research activities in label expansion of TNF inhibitors enhancing its application across various disease areas thus catalyzing the market growth
  • Rising prevalence of autoimmune disease across geographies and the use of TNF inhibitors for multiple autoimmune conditions catalyzing the market growth
  • Biosimilars are expected to increase market competition in the near future and ensure incessant growth during the forecast period from 2018 to 2026

Key Topics Covered

Chapter 1. Preface
1.1. Report Description
1.1.1. Study Purpose
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Market Segmentation
1.3. Research Scope
1.4. Research Methodology
1.4.1. Phase I - Secondary Research
1.4.2. Phase II - Primary Research
1.4.3. Phase III - Expert Panel Review
1.4.4. Assumptions

Chapter 2. Executive Summary
2.1. Global Tumor Necrosis Factor Inhibitors Market Portraiture
2.2. Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2017 (US$ Mn)
2.3. Tumor Necrosis Factor Inhibitors Market, by Application, 2017 (US$ Mn)
2.4. Tumor Necrosis Factor Inhibitors Market, by Geography, 2017 (US$ Mn)

Chapter 3. Global Tumor Necrosis Factor Inhibitors Market: Dynamics and Future Outlook
3.1. Overview
3.2. Market Dynamics
3.2.1. Market Drivers
3.2.1.1. Increased Prevalence of Autoimmune Diseases
3.2.1.2. Continuous Development of Biosimilars
3.2.2. Market Challenges
3.2.2.1. Challenge 1
3.2.3. Market Opportunities
3.2.3.1. Regulatory Support for Development of Biosimilars
3.3. Attractive Investment Proposition, by Geography, 2017
3.4. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 - 2026 (US$ Mn)
4.1. Overview
4.2. Adalimumab (Humira)
4.3. Certolizumab (Cimzia)
4.4. Etanercept (Enbrel)
4.5. Golimumab (Simponi)
4.6. Infliximab (Remicade)
4.7. Pipeline Analysis
4.7.1. Phase III Molecules (Forecast till 2026 in US$ Mn)
4.7.1.1. IBI303
4.7.1.2. HLX03
4.7.1.3. BCD-057
4.7.1.4. M923
4.7.2. Phase I & Phase II Molecules (Tabular Representation)

Chapter 5. Global Tumor Necrosis Factor Inhibitors Market, by Application, 2016 - 2026 (US$ Mn)
5.1. Overview
5.2. Crohn's Disease
5.3. Rheumatoid Arthritis
5.4. Psoriatic Arthritis
5.5. Plaque Psoriasis
5.6. Ulcerative Colitis
5.7. Ankylosing Spondylitis
5.8. Hidradenitis Suppurativa
5.9. Uveitis
5.10. Juvenile Arthritis

Chapter 6. Global Tumor Necrosis Factor Inhibitors Market, by Geography, 2016 - 2026 (US$ Mn)
6.1. Overview
6.2. North America Tumor Necrosis Factor Inhibitors Market, 2016 - 2026 (US$ Mn)
6.2.1. North America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 - 2026 (US$ Mn)
6.2.2. North America Tumor Necrosis Factor Inhibitors Market, by Application, 2016 - 2026 (US$ Mn)
6.2.3. North America Tumor Necrosis Factor Inhibitors Market, by Country, 2016 - 2026 (US$ Mn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Tumor Necrosis Factor Inhibitors Market, 2016 - 2026 (US$ Mn)
6.3.1. Europe Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 - 2026 (US$ Mn)
6.3.2. Europe Tumor Necrosis Factor Inhibitors Market, by Application, 2016 - 2026 (US$ Mn)
6.3.3. Europe Tumor Necrosis Factor Inhibitors Market, by Country, 2016 - 2026 (US$ Mn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Tumor Necrosis Factor Inhibitors Market, 2016 - 2026 (US$ Mn)
6.4.1. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016 - 2026 (US$ Mn)
6.4.2. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.4.3. Asia Pacific Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
6.4.3.1. Japan
6.4.3.2. China
6.4.3.3. Rest Of Asia Pacific
6.5. Latin America Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
6.5.1. Latin America Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
6.5.2. Latin America Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.5.3. Latin America Tumor Necrosis Factor Inhibitors Market, by Country, 2016-2026 (US$ Mn)
6.5.3.1. Mexico
6.5.3.2. Brazil
6.5.3.3. Rest of Latin America
6.6. Middle East & Africa (MEA) Tumor Necrosis Factor Inhibitors Market, 2016-2026 (US$ Mn)
6.6.1. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Drug Type, 2016-2026 (US$ Mn)
6.6.2. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Application, 2016-2026 (US$ Mn)
6.6.3. Middle East & Africa Tumor Necrosis Factor Inhibitors Market, by Region, 2016-2026 (US$ Mn)
6.6.3.1. GCC
6.6.3.2. Rest of Middle East & Africa

Chapter 7. Profiles
7.1. Abbvie, Inc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to Data Availability)
7.1.3. Product Portfolio
7.1.4. Key Developments
7.2. Amgen, Inc.
7.3. Biocad Biopharmaceutical Co.
7.4. Boehringer Ingelheim Pharmaceuticals, Inc.
7.5. EPIRUS Biopharmaceuticals, Inc.
7.6. Innovent Biologics, Inc.
7.7. Janssen Biotech, Inc.
7.8. Merck & Co., Inc.
7.9. Novartis A.G.
7.10. Pfizer, Inc.
7.11. Shanghai Henlius Biotech, Inc.
7.12. UCB S.A.

For more information about this report visit https://www.researchandmarkets.com/research/9kvs6m/global_tumor?w=5

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 



View original content:http://www.prnewswire.com/news-releases/global-tumor-necrosis-factor-tnf-inhibitors-market-2018-2026-a-181-13-billion-market-opportunity-by-2026--300675249.html

SOURCE Research and Markets

PR Newswire
www.prnewswire.com

Last updated on: 02/07/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.